Lansoprazole Zentiva

Lansoprazole, the active ingredient in Lansoprazole Zentiva, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease and as part of Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazole Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole Zentiva is a proton pump inhibitor indicated for several acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of the esophageal lining. - Erosive esophagitis: heals erosive lesions and reduces risk of recurrence. - Peptic ulcer disease: facilitates ulcer healing and lowers the chance of re‑bleeding. - Helicobacter pylori eradication (as part of combination therapy): enhances bacterial clearance when used with antibiotics.

Adverse reactions may occur with Lansoprazole Zentiva and are reported across a spectrum of frequency.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated colitis - Low magnesium (hypomagnesemia) - Liver enzyme abnormalities (hepatotoxicity)

Before initiating therapy, consider the following safety measures.

- Assess renal function: dose may need adjustment in severe renal impairment. - Monitor for infection: prolonged use can increase risk of gastrointestinal infections. - Avoid abrupt discontinuation: may cause rebound acid hypersecretion. - Use with caution in elderly patients: higher incidence of adverse events observed. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Lansoprazole Zentiva can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption and efficacy of ketoconazole. - Atazanavir: decreased plasma concentrations of atazanavir. - Clopidogrel: diminished activation of clopidogrel, reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: may raise serum digoxin levels; observe for toxicity. - Methotrexate: potential for increased methotrexate exposure; check renal function and drug levels.